Study
reported that only 208 (2.5%) patients had active cancer at baseline, as judged by treating physician at time of enrollment, and only 162 (2.0%) had active cancer at baseline as judged by a post hoc assessment that defined active cancer as the presence of solid measurable cancer or hematologic malignancy not in remission; excluding nonmelanoma skin cancers. EINSTEIN studies: data shown are for active cancer at baseline, defined as cancer diagnosis or treatment within 6 months before enrolment, or recurrent/metastatic cancer; another 167 patients developed active cancer during study, defined as new diagnosis or recurrence after randomization. Table 6 HIT, heparin-induced thrombocytopenia; HT Unctl, uncontrolled hypertension; NR, none reported; NSAID, nonsteroidal antiinflammatory drug; P-gp, P-glycoprotein; xULN, times upper limit of normal. a "x" indicates that feature was an exclusion criteria; "None" means that published reports clearly indicate that this feature was not an entry criteria; blank entry indicates that published reports do not specifically mention the feature as an entry criteria. b The list of exclusion criteria may be incomplete because complete study protocols were not available.
